HomeNew producsSpecialsMy accountFAQContact Us
Search
 

Use keywords to find the product you are looking for.

 
Categories
PGD2 Inhibitors
D-Cloprostenol
Ramatroban
SARMs
Ostarine 25mg / ml, 60ml
SARMs S4 25mg / ml, 60ml
SERMs
Clomiphene 3000mg, 60ml
Raloxifene 60mg /ml, 60ml
Tamoxifen (True Twenty) 1200mg, 60ml
Toremifene Citrate 1800mg, 30ml
Toremifene Citrate 3600mg, 60ml
b2 ADRENERGENIC AGONISTS
Albuterol 6mg/ml, 60ml
Clenbuterol 200mcg/ml, 30ml
Clenbuterol 200mcg/ml, 60ml
THYROID RELATED
T3 100mcg / ml, 60ml
T4 400mcg / ml, 60ml
AROMATASE INHIBITORS
Anastrozole 30mg, 30ml
Anastrozole 60mg, 60ml
Exemestane 10mg / ml, 30ml
Exemestane 10mg / ml, 60ml
Letrozole 150mg, 60ml
Letrozole 75mg / 30ml
IGF-1 PEPTIDES
IGF-1 DES 1 3, 1200mcg
IGF-1 Lr3 (10 vials)
IGF-1 Lr3 (3 Vials)
IGF-1 Lr3, 1200mcg
IGF-1 RH, 1200mcg
IGF-2 Lr3 1200mcg
MGF (IGF-1Ec) 2000mcg
IGF KITS
IGF-1 DES 1 3 KIT Receptor 1200mcg
IGF-1 Lr3 KIT Receptor 1200mcg
IGF-2 Lr3 Kit Receptor 1200mcg
MELANOTROPIN PEPTIDES
Melanotan II (10 vials) 100mg
Melanotan II 10mg
Melanotan II 30mg (3 Vials)
PT-141 (Bremalanotide) 10mg
SECRETOGOGUE PEPTIDES
CJC 1295 DAC, 2000mcg
CJC 1295 DAC, 2000mcg (3 vials)
CJC-1293 (GRF [1 29]) (3 vials)
CJC-1293 (GRF [1-29]) 2000mcg
GHRP-2 (4 Vials)
GHRP-2 (receptor) 5mg
GHRP-6 (receptor), 5mg
GHRP-6, (4 vials)
GnRH, 2000mcg
Hexarelin, 2000mcg
Ipamorelin, 2000mcg
Tesamorelin, 5 vial kit, 10mg
PEPTIDES
Ghrelex (D-Lys≥ GHRP-6)
Oxytocin, 1200iu
Phospho DSIP 1000mcg
Thymosin Beta 4, 8mg (4 vial pack)
MORE RESEARCH CHEM'S
AICAR 100mg
Dapoxetine HCL 30mg/ml, 30ml
GW1516, 150mg
Ketotifen Fumarate 120mg 60ml
Rimonabant 1200mg, 60ml
Yohimbine HCL, 10mg/ml, 30ml
SELECTIVE ANTI-ANDROGENS
Cortexolone 17-Alpha Propionate
Finasteride 150mg, 30ml
PDE5 INHIBITORS
Avanafil 50mg / ml, 60ml
Sildenafil Citrate 750mg, 30ml
Tadalafil 30mg/ml, 30ml
Tadalafil 30mg/ml, 60ml
Vardenafil 300mg, 30ml
NOOTROPICS
Dihydroergotoxine (Ergotox)
Meclofenoxate, 60g
Pramiracetam 30g
Selegiline 300mg, 30ml
PROLACTIN ANTAGONISTS
Cabergoline 0.5mg / ml, 30ml
Pramipexole Hydrochloride 60mg, 60ml
A.G.E. INHIBITORS / BREAKERS
ALT-711 (thiazolium chloride), 15g
Aminoguanidine HCL 4.5g, 60ml
TELOMERASE ACTIVATORS
Astragaloside IV 20mg / ml, 60ml
Cycloastragenol 5mg / ml, 60ml
HEPATOXICITY INHIBITORS
Silibinin 100mg/ml, 60ml
Ursodeoxycholic Acid, 30g
COMBINATION SPECIALS
AICAR + GW1516
Clen + Keto + Yohimbine
Tamox / Clom / Anast
MISCELLANEOUS
Custom Order: CO_061013NH
Expedited Service
Foreign Reship Fee
Legal Disclaimer for Download
Priority Shipping
Shipping Insurance $100-$299
Shipping Insurance $1000-$3000
Shipping Insurance $25-$99
Shipping Insurance $300-$599
Shipping Insurance $600-$999
Special Handling Fee $16
Special Handling Fee $30
test

GW1516, 150mg

 [GW15]
 $119.00 
GW1516, 150mg

GW1516

 

GW1516, also written GW 50516, is a drug and research chemical developed by pharmaceutical client GlaxoSmithKline, which acts as a PPARδ (peroxisome proliferator activated receptor delta) modulator and selective agonist.[1][2] GW1516 activates AMP-K (5' adenosine monophosphate-activated protein kinase) and stimulates skeletal muscle glucose uptake.[3]

 

GW1516 has been demonstrated to effectively reverse metabolic abnormalities in obese men with metabolic syndrome (a pre-diabetic condition), likely due to the fact that it stimulus fatty acid oxidation.[4]

 

GW1516 holds promise for treating obesity and adiposity and has been touted, much like AICAR, as "exercise in a pill," etc.[6]  In conjunction with AICAR, an AMPK agonist which acts synergistically with GW1516, significant increases in exercise endurance have been demonstrated in animal studies.[5]

 

Ali et al write on the role of PPARk in the body's normal functioning:

 Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor superfamily of ligand-activated transcriptional regulators. PPARdelta has an established role in metabolism, wound healing, and angiogenesis. However, little is known about its function in endothelial homeostasis. [7]

 

Ali et also infer from their data that PPARk agonists may be a hopeful area of study for treating vascular issues or perhaps preventing vascular issues by promoting stress resistance:

We have identified an important relationship between PPARdelta, PGC1alpha, and haem oxygenase-1, demonstrating that haem oxygenase-1 induction plays an important role in cytoprotective actions of PPARdelta ligands in vascular endothelium. In light of the protective effects of haem oxygenase-1 against atherogenesis, we suggest that PPARdelta represents a potentially important therapeutic target in the vasculature.[7]

 

Foreman et al conclude that "proliferation of the C20 mouse mammary gland cancer cell line is inhibited by ligand activation of PPARbeta/delta due in part to increased apoptosis" meaning that as an additive therapy, PPARdelta agonists such as GW1516 may be useful for treating certain types of cancer or for promoting continued remission.[8]

 

Dimoupolos et al write:

Peroxisome proliferator-activated receptor-delta (PPARdelta) activation enhances skeletal muscle fatty acid oxidation and improves whole body glucose homeostasis and insulin sensitivity. Recently, GW501516, a selective PPARdelta agonist, was reported to increase glucose uptake in human skeletal myotubes by an AMPK-dependent mechanism that may contribute to the improved glucose tolerance. Here, we demonstrate that whilst GW501516 increases expression of PGC-1alpha and CPT-1 and stimulates fatty-acid oxidation in L6 myotubes, it fails to enhance insulin sensitivity, AMPK activity or glucose uptake and storage. Our findings exclude sarcolemmal glucose transport as a potential target for the therapeutic action of PPARdelta agonists in skeletal muscle.[9]

 

Wang et al show that PPARdelta agonists are useful targets for investigation regarding obesity prevention:

[T]argeted activation of PPARdelta in adipose tissue specifically induces expression of genes required for fatty acid oxidation and energy dissipation, which in turn leads to improved lipid profiles and reduced adiposity. ...In vitro, activation of PPARdelta in adipocytes and skeletal muscle cells promotes fatty acid oxidation and utilization. Our findings suggest that PPARdelta serves as a widespread regulator of fat burning and identify PPARdelta as a potential target in treatment of obesity and its associated disorders.[10]

 

 

Narkar et al, authors of the pioneering study on AICAR, highlight some of the reasons GW1516 and other "exercise mimetics" are desirable for treating conditions prevalent in the current medical milieu:

The benefits of endurance exercise on general health make it desirable to identify orally active agents that would mimic or potentiate the effects of exercise to treat metabolic diseases. Although certain natural compounds, such as reseveratrol, have endurance-enhancing activities, their exact metabolic targets remain elusive. We therefore tested the effect of pathway-specific drugs on endurance capacities of mice in a treadmill running test. We found that PPARbeta/delta agonist and exercise training synergistically increase oxidative myofibers and running endurance in adult mice. Because training activates AMPK and PGC1alpha, we then tested whether the orally active AMPK agonist AICAR might be sufficient to overcome the exercise requirement. Unexpectedly, even in sedentary mice, 4 weeks of AICAR treatment alone induced metabolic genes and enhanced running endurance by 44%. These results demonstrate that AMPK-PPARdelta pathway can be targeted by orally active drugs to enhance training adaptation or even to increase endurance without exercise.[11]

 

Citations:

[1] Sznaidman ML, Haffner CD, Maloney PR, Fivush A, Chao E, Goreham D, Sierra ML, LeGrumelec C, Xu HE, Montana VG, Lambert MH, Willson TM, Oliver WR Jr, Sternbach DD (May 2003). "Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity". Bioorg. Med. Chem. Lett. 13 (9): 1517–21.

[2]Dimopoulos N, Watson M, Green C, Hundal HS (October 2007). "The PPAR delta agonist, GW501516, promotes fatty acid oxidation but has no direct effect on glucose utilization or insulin sensitivity in rat L6 skeletal muscle cells". FEBS Lett. 581 (24): 4743–8.

[3]Krämer DK, Al-Khalili L, Guigas B, Leng Y, Garcia-Roves PM, Krook A  (July 2007). "Role of AMP kinase and PPAR delta in the regulation of lipid and glucose metabolism in human skeletal muscle". J. Biol. Chem. 282 (27): 19313–20.

[4]Risérus U, Sprecher D, Johnson T, Olson E, Hirschberg S, Liu A, Fang Z, Hegde P, Richards D, Sarov-Blat L, Strum JC, Basu S, Cheeseman J, Fielding BA, Humphreys SM, Danoff T, Moore NR, Murgatroyd P, O'Rahilly S, Sutton P, Willson T, Hassall D, Frayn KN, Karpe F (February 2008). "Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men". Diabetes 57 (2): 332–9.

[5]Narkar VA, Downes M, Yu RT, Embler E, Wang Y-X, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, Kang H, Shaw RJ,2 Evans RM (August 2008). "AMPK and PPAR Agonists Are Exercise Mimetics". Cell 134: 1–11.

[6] "Exercise In A Pill: Researchers Identify Drugs That Enhance Exercise Endurance". Science News. ScienceDaily. 2008-08-01. (Science Daily)

[7]Ali F, Ali NS, Bauer A, Boyle JJ, Hamdulay SS, Haskard DO, Randi AM, Mason JC. PPARdelta and PGC1alpha act cooperatively to induce haem oxygenase-1 and enhance vascular endothelial cell resistance to stress. Cardiovasc Res. 2010 Mar 1;85(4):701-10.

[8]Foreman JE, Sharma AK, Amin S, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor-beta/delta

(PPARbeta/delta) inhibits cell growth in a mouse mammary gland cancer cell line. Cancer Lett. 2010 Feb 28;288(2):219-25.

[9] Dimopoulos N, Watson M, Green C, Hundal HS.  The PPAR delta agonist, GW501516, promotes fatty acid oxidation but has no direct effect on glucose utilization or insulin sensitivity in rat L6 skeletal muscle cells. FEBS Lett. 2007 Oct 2;581(24):4743-8.

[10]Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell. 2003 Apr 18;113(2):159-70.

[11] Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, Kang H, Shaw RJ, Evans RM. AMPK and PPARdelta agonists are exercise mimetics. Cell. 2008 Aug 8;134(3):405-15.

 

*The latter article is intended for educational / informational purposes only. THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. Bodily introduction of any kind into humans or animals is strictly forbidden by law.

This product was added to our catalog on Friday 27 November, 2009.
Reviews Add to Wish List
Quantity:     
Shopping Cart
  Now in your cart 0 items
 
Your Account
 
Your Email Address
Your Password
 
Information
   
BestSellers
   
Featured
 
  AICAR 100mg
 
 

AICAR 100mg

$98.00
Comments
 
  Melanotan II 10mg
 
 

Melanotan II 10mg

This is as good as it gets out there. Cost is incredible and the ...
$98.00
Who's Online
  There currently are 29 guests and 
1 member online.